A randomized controlled trial comparing perioperative vs. postoperative mFOLFOX6 for lower rectal cancer with suspected lateral pelvic lymph node metastasis (JCOG1310): a phase II/III randomized controlled trial. (30th May 2022)

• Record Type: Journal Article
• Authors: Ohue, Masayuki; Iwasa, Satoru; Mizusawa, Junki; Kanemitsu, Yukihide; Shiozawa, Manabu; Nishizawa, Yusuke; Ueno, Hideki; Katsumata, Kenji; Yasui, Masayoshi; Tsukamoto, Shunsuke; Katayama, Hiroshi; Fukuda, Haruhiko; Shimada, Yasuhiro
• Is Part Of: Japanese journal of clinical oncology. Volume 52:Number 8(2022)
• Page Start: 842
• Page End: 850
• Publication Date: 2022-05-30
• Subjects: rectal cancer -- lateral pelvic lymph node metastasis -- lateral lymph node dissection -- perioperative chemotherapy -- postoperative chemotherapy; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyac080
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract: Objective: The optimal perioperative chemotherapy for lower rectal cancer with lateral pelvic lymph node metastasis remains unclear. We evaluated the efficacy and safety of perioperative mFOLFOX6 in comparison with postoperative mFOLFOX6 for rectal cancer patients undergoing total mesorectal excision with lateral lymph node dissection. Methods: We conducted an open label randomized phase II/III trial in 18 Japanese institutions. We enrolled patients with histologically proven lower rectal adenocarcinoma with clinical pelvic lateral lymph node metastasis who were randomly assigned (1:1) to receive postoperative mFOLFOX6 (12 courses of intravenous oxaliplatin [85 mg/m 2 ] with L-leucovorin [200 mg/m 2 ] followed by 5-fluorouracil [400 mg/m 2, bolus and 2400 mg/m 2, continuous infusion, repeated every 2 weeks]) or perioperative mFOLFOX6 (six courses each preoperatively and postoperatively). The primary endpoint was overall survival (OS). The trial is registered with Japan Registry of Clinical Trials, number jRCTs031180230. Results: Between May 2015, and May 2019, 48 patients were randomized to the postoperative arm ( n = 26) and the perioperative arm ( n = 22). The trial was terminated prematurely due to poor accrual. The 3-year OS in the postoperative and perioperative groups were 66.1 and 84.4%, respectively (HR 0.58, 95% CI [0.14–2.45], one-sided P = 0.23). The pathological complete response rate in the perioperative group was 9.1%. Grade 3 postoperative surgical complications were more frequently observed in the perioperative arm (50.0 vs. 12.0%). One treatment-related death due to sepsis from pelvic infection occurred in the postoperative group. Conclusions: Perioperative mFOLFOX6 may be an insufficient treatment to improve survival of lower rectal cancer with lateral pelvic lymph node metastasis. Abstract : This study investigated the efficacy and safety of perioperative mFOLFOX6 in comparison to postoperative mFOLFOX6 for lower rectal cancer patients undergoing total mesorectal excision with lateral lymph node dissection.